BOLT Stock Price, Bolt Biotherapeutics, . Quote, Chart

Market Summary

USD1.11-0.05

Market Closed

-4.31%

BOLT Stock Price

View Fullscreen

BOLT RSI Chart

BOLT Valuation

Market Cap

42.3M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

5.37

Price/Free Cashflow

-0.61

BOLT Price/Sales (Trailing)

BOLT Profitability

Return on Equity

-61.38%

Return on Assets

-43.31%

Free Cashflow Yield

-164.76%

BOLT Fundamentals

BOLT Revenue

Revenue (TTM)

7.9M

Rev. Growth (Yr)

48.05%

Rev. Growth (Qtr)

-17.37%

BOLT Earnings

Earnings (TTM)

-69.2M

Earnings Growth (Yr)

10.47%

Earnings Growth (Qtr)

-10.12%

Breaking Down BOLT Revenue

Last 30 days

-9.0%

Last 90 days

3.7%

Trailing 12 Months

-27.0%

How does BOLT drawdown profile look like?

BOLT Financial Health

Current Ratio

5.17

BOLT Investor Care

Shares Dilution (1Y)

0.81%

Diluted EPS (TTM)

-1.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.7M	6.8M	7.2M	7.9M
2022	2.2M	3.5M	4.8M	5.7M
2021	0	269.0K	970.0K	1.4M
2020	0	0	0	257.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bolt Biotherapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 12, 2023	quinn william p.	bought	7,125	0.95	7,500	chief financial officer
Dec 06, 2023	quinn william p.	bought	1,955	0.782	2,500	chief financial officer
Dec 06, 2023	perez edith a.	bought	1,955	0.782	2,500	chief medical officer
Dec 06, 2023	yonehiro grant	bought	1,955	0.782	2,500	chief business officer
Dec 06, 2023	schatzman randall c	bought	1,955	0.782	2,500	chief executive officer
Nov 30, 2023	engleman edgar	sold	-92,799	0.8581	-108,145	-
Nov 30, 2023	engleman edgar	sold	-12,814	0.8581	-14,934	-
Nov 29, 2023	engleman edgar	sold	-20,542	0.906	-22,674	-
Nov 29, 2023	engleman edgar	sold	-2,836	0.906	-3,131	-
Nov 21, 2023	vivo capital viii, llc	sold	-1,536	0.9	-1,707	-

Which funds bought or sold BOLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	985,961	4,929,810	0.39%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	11.00	56.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.74	81,628	1,042,860	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	63,016	63,016	-%
Feb 14, 2024	Board of Trustees of The Leland Stanford Junior University	reduced	-4.96	18,510	805,891	0.05%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-13.83	-213,747	2,754,030	-%
Feb 14, 2024	Royal Bank of Canada	added	394	-	-	-%
Feb 14, 2024	ORBIMED ADVISORS LLC	unchanged	-	123,280	1,725,920	0.03%

Are Funds Buying or Selling BOLT?

Are funds buying BOLT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BOLT

No. of Funds

Unveiling Bolt Biotherapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	9.6%	3,652,244	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.2%	6	SC 13G/A
Feb 13, 2024	vivo capital viii, llc	4.8%	1,821,483	SC 13G/A
Feb 12, 2024	pivotal bioventure partners fund i, l.p.	8.1%	3,058,419	SC 13D/A
Apr 20, 2023	tang capital partners lp	7.2%	2,732,250	SC 13G
Feb 14, 2023	citadel advisors llc	7.3%	6	SC 13G/A
Feb 13, 2023	suvretta capital management, llc	0%	0	SC 13G/A
Jan 04, 2023	novo holdings a/s	0%	0	SC 13D/A
Dec 28, 2022	novo holdings a/s	6.7%	2,534,465	SC 13D/A
Jul 15, 2022	novo holdings a/s	9.8%	3,703,991	SC 13D/A

Recent SEC filings of Bolt Biotherapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Bolt Biotherapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Bolt Biotherapeutics, Inc. News

Latest updates

Bolt Biotherapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-17.4%	2,089	2,528	1,433	1,826	1,411	2,112	1,393	813	508	752	176	-	42.00	51.00	164
Operating Expenses	5.5%	21,855	20,711	21,265	20,241	22,451	24,458	24,452	24,689	27,583	24,278	23,761	16,922	12,405	11,177	8,909
S&GA Expenses	-3.9%	5,533	5,760	5,621	5,616	5,606	5,485	5,532	6,304	5,099	4,941	4,054	2,058	2,865	2,011	2,122
R&D Expenses	9.2%	16,322	14,951	15,644	14,625	16,845	18,973	18,920	18,385	22,484	19,337	19,707	14,864	9,540	9,166	6,787
Net Income	-10.1%	-17,903	-16,257	-18,057	-16,980	-19,997	-21,759	-22,664	-23,678	-27,157	-23,395	-23,585	-31,035	-10,001	-11,059	-8,633
Net Income Margin	11.3%	-8.79*	-9.90*	-11.32*	-12.07*	-15.38*	-19.74*	-27.96*	-43.49*	-68.66*	-105.64*	-331.13*	-236.30*	-	-	-
Free Cashflow	15.6%	-14,271	-16,914	-15,144	-23,402	-18,136	-14,186	-21,216	-24,919	-18,356	-19,742	-4,689	-13,788	-13,666	-13,105	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-8.9%	160	175	191	206	228	246	260	283	308	334	347	325	47.00
Current Assets	-15.7%	106	125	131	132	173	175	181	196	189	222	248	271	25.00
Cash Equivalents	18.0%	11.00	9.00	13.00	15.00	9.00	11.00	23.00	44.00	27.00	24.00	58.00	95.00	6.00
Net PPE	-5.9%	5.00	5.00	6.00	6.00	6.00	7.00	7.00	7.00	6.00	6.00	5.00	4.00	4.00
Liabilities	-0.1%	47.00	47.00	49.00	48.00	56.00	57.00	52.00	54.00	58.00	59.00	51.00	21.00	46.00
Current Liabilities	9.1%	20.00	19.00	18.00	16.00	23.00	24.00	19.00	19.00	21.00	24.00	19.00	12.00	11.00
Shareholder's Equity	-12.1%	113	128	142	158	172	188	208	228	250	275	296	303	-
Retained Earnings	-5.2%	-364	-346	-330	-312	-295	-275	-253	-230	-206	-179	-156	-132	-108
Additional Paid-In Capital	0.5%	477	475	472	470	468	465	463	460	457	455	452	436	3.00
Shares Outstanding	0.4%	38.00	38.00	38.00	38.00	38.00	37.00	37.00	37.00	37.00	32.00	29.00	21.00	2.00
Float	-	-	-	32.00	-	-	-	51.00	-	-	-	383	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	14.8%	-14,265	-16,749	-15,112	-23,399	-17,952	-13,451	-20,787	-24,314	-17,794	-18,727	-3,986	-16,559	-12,890	-12,515	-12,265	-9,638
Share Based Compensation	13147.0%	4,372	33.00	39.00	2,476	4,290	100	100	2,919	4,167	100	100	2,109	569	403	223	225
Cashflow From Investing	24.9%	15,809	12,658	13,580	28,991	16,435	1,450	-868	40,845	21,033	-16,111	-46,602	-190,521	1,704	-13,095	4,407	-13,608
Cashflow From Financing	-	106	-	-	-	144	-	252	107	495	185	13,409	297,019	-1,065	-923	41,551	34.00

BOLT Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 7,876	$ 5,729
Operating expenses:
Research and development	61,542	73,123
General and administrative	22,530	22,927
Total operating expense	84,072	96,050
Loss from operations	(76,196)	(90,321)
Other income, net
Interest income	6,999	2,223
Total other income, net	6,999	2,223
Net loss	(69,197)	(88,098)
Net unrealized gain (loss) on marketable securities	956	(598)
Comprehensive loss	$ (68,241)	$ (88,696)
Net loss per share, basic	$ (1.83)	$ (2.36)
Net loss per share, diluted	$ (1.83)	$ (2.36)
Weighted-average shares outstanding, basic	37,811,984	37,358,425
Weighted-average shares outstanding, diluted	37,811,984	37,358,425

BOLT Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,810	$ 9,244
Short-term investments	91,379	159,644
Prepaid expenses and other current assets	3,519	3,858
Total current assets	105,708	172,746
Property and equipment, net	4,957	6,453
Operating lease right-of-use assets	19,120	22,072
Restricted cash	1,765	1,565
Long-term investments	26,413	23,943
Other assets	1,821	1,028
Total assets	159,784	227,807
Current liabilities:
Accounts payable	2,987	3,594
Accrued expenses and other current liabilities	12,486	15,140
Deferred revenue	2,201	1,993
Operating lease liabilities	2,782	2,391
Total current liabilities	20,456	23,118
Operating lease liabilities, net of current portion	17,437	20,220
Deferred revenue, non-current	9,107	12,921
Other long-term liabilities	43	42
Total liabilities	47,043	56,301
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value, authorized shares - 10,000,000 shares authorized at December 31, 2023 and 2022; zero shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 38,114,606 and 37,797,902 shares issued and outstanding at December 31, 2023 and 2022, respectively	1	0
Additional paid-in capital	476,988	467,513
Accumulated other comprehensive gain (loss)	37	(919)
Accumulated deficit	(364,285)	(295,088)
Total stockholders' equity	112,741	171,506
Total liabilities, convertible preferred stock, and stockholders' equity	$ 159,784	$ 227,807

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

CEO	Dr. Randall C. Schatzman Ph.D.
WEBSITE	boltbio.com
INDUSTRY	Biotechnology
EMPLOYEES	94

Bolt Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Bolt Biotherapeutics, Inc.? What does BOLT stand for in stocks?

BOLT is the stock ticker symbol of Bolt Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bolt Biotherapeutics, Inc. (BOLT)?

As of Fri Apr 26 2024, market cap of Bolt Biotherapeutics, Inc. is 42.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BOLT stock?

You can check BOLT's fair value in chart for subscribers.

What is the fair value of BOLT stock?

You can check BOLT's fair value in chart for subscribers. The fair value of Bolt Biotherapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bolt Biotherapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BOLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bolt Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BOLT is over valued or under valued. Whether Bolt Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Bolt Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BOLT.

What is Bolt Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, BOLT's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 5.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BOLT PE ratio will change depending on the future growth rate expectations of investors.